HFSA Annual Scientific Meeting 2022

September 30, 2022 - October 3, 2022 | Gaylord National Harbor | Washington, DC

Late Breaking Clinical Trials

HFSA Annual Scientific Meeting 2022 Banner Graphic


Late Breaking Clinical Trial submissions are now closed

Late Breaking Clinical Trials is an always-popular session where speakers present the results of a new research in heart failure. Featured on a plenary session stage (Session I), Late Breaking Clinical Trials provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.

Late Breaking Clinical Trials Session I (Sunday Plenary)
8:00 AM - 9:30 AM | Potomac A/B

  • Effect Of Empagliflozin On Clinical Events In Patients Hospitalized For Acute Heart Failure: Results From EMPULSE
  • Dapagliflozin In Heart Failure With Improved Ejection Fraction
  • Voice Analysis-based Telemonitoring Predicts Worsening Heart Failure Events With Markedly Greater Sensitivity Than Daily Weight Monitoring
  • Oral Sodium To Preserve Renal Efficiency In Acute Heart Failure (OSPREY-AHF): A Single-center, Double-Blind, Randomized, Placebo-controlled Trial
  • Effect Of Sacubitril/valsartan On Mitral Regurgitation In Heart Failure With Reduced Ejection Fraction. The PROVE-HF Study
  • Blood Pressure, Dapagliflozin, And Cardiovascular Outcomes In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: DELIVER

Learn more about HFSA Annual Scientific Meeting 2022 Daily Plenary Sessions >>

Late Breaking Clinical Trials Session II
9:45 AM - 10:45 AM | Potomac C

  • The Effects Of Istaroxime In Patients With Pre-cardiogenic Shock Due To Acute Heart Failure - Dose Response
  • Usefulness Of Left Atrial Appendage Exclusion During Left Ventricular Assist Device Implantation: An Outcomes Analysis From The Momentum 3 Randomized Clinical Trial
  • Improvement In KCCQ Scores In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Aficamten In The REDWOOD-HCM OLE Study
  • GRAHF2: Genomic Response Analysis Of Heart Failure Therapy In African Americans

Embargo Policy

Abstracts accepted are embargoed for release until the time of presentation at the Heart Failure Society of America’s Annual Scientific Meeting.

The standard is that any company can announce at any time the following:

  1. Announcement that trial is completed
  2. That results will be presented at so and so date in such and such a meeting
  3. What did the trials assess – basic design, questions, study population, interventions etc.


  • Submission Portal Opens: May 16, 2022
  • Submission Deadline: CLOSED

Clinical trials accepted for presentation will be: 

  • Presented during the Late Breaking Clinical Trials session - one of three Plenary Sessions to be held at ASM 2022!
  • Published in an issue of the Journal of Cardiac Failure after the meeting. Authors will have the ability to update the submitted abstract prior to publication. JCF encourages all accepted Late Breaking Clinical Trials to submit full papers for further consideration

All late breaking data is embargoed until the day of Late Breaking Clinical Trials session.

If an accepted late breaking clinical trial abstract was submitted and accepted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by August 3, 2022.